2024-05-26 02:02:40 ET
Summary
- Verastem Oncology's stock dropped significantly after the announcement of data from the RAMP-205 study investigating avutometinib in combination with standard chemotherapy for metastatic pancreatic cancer.
- The study showed promising early efficacy signal with 87% response rate, but also a high rate of serious adverse events.
- Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)